SMMTNGMHealthcare·Biotechnology#14 in industry

Summit Therapeutics Inc.

Reports in 3d· 2026-04-30

+39.1% · 90d

$22.12

+0.04 (+0.18%)

After-Hours $22.42(+0.30)

News

(1)

April 2026

Apr 6, 20263 weeks agoPRE 14AHealthcare

Summit Therapeutics Inc. — PRE 14A Filing

SMMTSummit Therapeutics Inc.

# 🧾 What This Document Is This is a **PRELIMINARY proxy statement (PRE 14A)** for Summit Therapeutics. It's the "advance notice" and agenda for the company's upcoming virtual annual shareholder meeting. Its purpose is to give shareholders the information they need to vote on important company matte

Read summaryView on SEC EDGAR

Key Data

Market Cap$17.17B

Open$22.08

Prev Close$22.08

Day Range$21.81 – $22.55

52W Range$13.83 – $30.98

Volume3,677,731

P/E (TTM)—

EPS$-1.44

Dividend Yield—

Beta-1.37

Price Target$31.10(+40.6%)

Next Earnings2026-04-30(3d)

Analyst Ratings

Strong Buy17 analysts

Buy 12Hold 4Sell 1

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Healthcare · Biotechnology

265 employees

www.smmttx.com